Tohoku Univ. Technology

Small molecule inhibitors of Vasohibin-2

Inhibitors targeting VASH2, the highly expressed protein in cancer

Since the patent application has not been published, the structural of the five screened compounds have not been disclosed. Please feel free to contact us as we can disclose the information after signing a non-disclosure agreement.

Overview

Angiogenesis is known to be involved in the development and progression of cancer, diabetic nephropathy, heart failure, arteriosclerosis, and nervous system diseases. The inventors have discovered Vasohibin1 (VASH1), an angiogenesis inhibitor produced by vascular endothelial cells, Vasohibin2 (VASH2), a homolog of Vasohibin1, and Small Vasohibin Binding Protein (SVBP), which enhances their stability, and have developed new therapies based on enhancing the effects of VASH1 or inhibiting VASH2 (see "Related Inventions").

The present invention was screened from a small molecule compound library, and obtained five small molecule inhibitors that do not inhibit the binding of VASH1 and SVBP, but selectively inhibits the binding of VASH2 and SVBP.

Features・Outstandings



Five small molecules were found to inhibit the binding of VASH2 to SVBP more than the binding of VASH1 to SVBP.

Possible Applications

- Small molecule drugs for pancreatic and other cancers
- Therapeutic agents targeting VASH2

Related Inventions

[1] IP No. : JP6300373 (Admin No. T12-072)
[2] IP No. : JP7202662 (Admin No. T18-447)

IP Data

IP No.	:	PCT/JP2024/013273
Inventor	:	SATO Yasufumi, SUZUKI Yasuhiro
Admin No.	:	T23-047

Contact

Tohoku Techno Arch Co., Ltd.
Please visit CONTACT here